Ms. Tassell joined Mirati in October 2013 and was named Vice President of Clinical Science in October 2017. She has more than 20 years of experience in clinical drug development. Prior to joining Mirati, she was Senior Director of Clinical Development at Aragon Pharmaceuticals located in San Diego. At Aragon, she managed the apalutamide (ERLEADA™) program while it was in development and prior to the Aragon acquisition by Johnson & Johnson in 2013. Ms. Tassell’s experience includes positions of increasing responsibility at Pfizer from 2000-2013, which involved supporting clinical development activities for oncology programs including NDA submissions for sunitinib (SUTENT®) and crizotinib (XALKORI®). Ms. Tassell started her career with Parexel International in Boston, Massachusetts. Ms. Tassell has a B.S. degree in Psychology from Northeastern University, Massachusetts.